life scienc tool diagnost
reason report
highlight ashg momentum across genom
bottom line recent attend american societi
human genet ashg meet assess uptak
genom sequenc applic broadli also spoke
medacorp specialist uptak novaseq consum
convers suggest firmli becom consum
stori long-term prime flowcel pois drive next leg
adopt novaseq among lower-throughput custom
larg project uk genom increasingli come
tabl drive multi-year demand acquisit edico
dragen comput platform necessari handl increasingli
larg dataset remain confid meet exceed
guid novaseq instal year among genom
compani continu recommend op op op
op univers increas estim
pt
prime flowcel could key next leg novaseq growth stori
see lower-output prime flowcel next leg
growth stori broader lab custom
upgrad novaseq make truli multi-year replac cycl
recal custom prior novaseq launch
high-throughput broader lower-
throughput genom center prime sp flowcel
line hiseq output desir lower-
throughput lab still cheaper price/gb
increasingli lever consum drive gross
margin even higher long-term believ pois
margin even higher despit near-term nois instrument instal
believ continu tilt scale toward consum
compar current consumables/instru mix ex
servic enhanc corpor gross margin beyond
long-term view sequenc consum deliv gross
margin vs instrument gross margin
demand genom larger project increas like
acceler price drop uk recent announc
sequenc genom next year would requir
least novaseq annual novaseq gener
human genom year current flow cell significantli
higher initi plan genom england gel project
massiv compar genom nih us program
sequenc next year believ countri
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
also step forward larger sequenc project drive increasingli
sequenc consum
ashg takeaway demand remain strong sequenc applic
continu grow seek lower sequenc cost
recent attend american societi human genet ashg assess uptak
genom sequenc applic also gain feedback lab medacorp
specialist continu uptak novaseq consum
medacorp specialist custom convers suggest
becom consum stori long-term demand consum pull-
continu ramp
output econom prime flowcel pois drive adopt novaseq
among lower-throughput custom custom
novaseq run drive uptak smaller benchtop instrument includ i-seq qualiti
control qc sampl prep reagent peer includ agil
single-cel genom larg genom remain import driver growth research
acquisit edico dragen comput platform help eas burden
large-scal dataset potenti integr novaseq eas data output
process concern genom realiz long-term
base convers also remain confid meet exceed guid
novaseq instal year among genom compani continu recommend
op op op op univers
stori increasingli lever consum drive gross margin
believ pois becom consumables-driven enterpris long-term drive gross
margin even higher convers custom ashg also confirm view
custom see novaseq stay longer tradit hiseq
instrument expect upgrad everi year
despit near-term nois instrument instal believ continu deriv
higher revenu consum beyond current consumables/instru mix ex
servic enhanc corpor gross margin beyond long-term view
sequenc consum gener deliv gross margin vs instrument
gross margin recal microarray slightli lower gross margin vs sequenc
consum microarray consum account ilmn revenu
also spoke two genom center spend excess ilmn reagent
annual like spend slightli higher next year project get fund
genom center gener hard time predict demand multipl year given
number project genom center lever come appear
genom center continu see growth sequenc volum long-term even
fewer sampl given quarter also recal ilmn revenu
lever clinic sequenc increasingli diagnost lab genom
center academ core
prime sp flowcel like provid next leg novaseq growth stori
see lower output prime flowcel next leg growth stori
broader lab custom upgrad novaseq make truli multi-
year replac cycl recal custom prior novaseq launch
high-throughput broader lower-throughput prime sp
flowcel line hiseq output desir lower-
throughput lab still cheaper price/gb lend confid
view novaseq see new box placement low-throughput lab
beyond novaseq hand lab could scale larger project need
util flowcel
figur view ilmn account novaseq launch sinc novaseq penetr
account come new high-throughput sequenc
custom leav account still upgrad novaseq potenti
prime flowcel
prime sp util flowcel restrict imag portion flowcel
thu gener vs gb control via rfid barcod place
flowcel prime kit avail cycl configur output
cycl much line output hiseq compar
cost rapid run hiseq appear price per gb novaseq
cheaper make much easier broader lower-throughput lab switch novaseq
despit low-throughput access high capac system like novaseq catalyz
growth lab believ lab like use sequenc capac longer-
term thu drive consum volum increasingli higher revenu
lab typecustom typemix customersestim hiseq customersestim hiseq instrumentsinstru per customerlow-mid thoughput center hiseq life scienc tool diagnost
demand genom larger project increas await
price per gb drop initi larger project
uk dept social care recent announc sequenc genom
next year would requir novaseq annual novaseq gener
human genom year current flow cell significantli higher initi
plan genom genom england gel project massiv compar
genom nih us program sequenc next year us
sequenc fund also split way center includ baylor broad institut
univers washington base convers medacorp specialist us
expect ramp sequenc util mircoarray
medacorp specialist also expect lower price per gb vs current order initi
large-scal sequenc project much line thesi ilmn
custom compet gain lower sequenc cost improv output
profit drive higher sequenc volum given momentum higher number
genom conduct uk china believ countri also step
forward larger sequenc project drive increasingli sequenc consum
volume-bas discount could acceler uptak
consum top-tier high throughput lab
medacorp specialist continu suggest broader discount lab will spend
per year consum commit could see discount excess
sequenc consum hand lab world consum
consum annual see ilmn attempt assess price elast
market higher end
also believ like provid discount current flowcel drive
elast demand market rather introduc flowcel near-term
major convers custom continu suggest reach
peak level util novaseq suggest new flowcel launch
acceler demand lower price per flowcel
train dragen edico remain import acquisit
data balloon
believ ilmn recent acquisit edico genom like acceler data analysi
whole genom computer- intens applic custom use applic
within cloud on-sit recal acquir edico genom dragen platform
dragen platform bioinformat solut provid faster data analysi
whole human genom exom smaller project -- via acceler comput hardwar
use fpga field programm gate array gpu graphic process faster
code new see provid solut current custom also
potenti longer-run could see incorpor dragen novaseq
hardwar acceler data convers gener size data continu
figur dragen comput hardwar fpga field programm gate array use
acceler comput task hardwar commonli use computer-intens
applic acceler time result could potenti use dragen fpga card
softwar within novaseq enhanc data output file size continu increas
iseq continu gain traction qc platform prior
spoke number custom see ilmn smallest sequenc use
qc system load sampl onto novaseq run vs stand-alone sequenc
medacorp specialist dont see iseq competit qualiti assurance/qu control qa/qc
current conduct agil fragment analyz aati system dna fragment
iseq like use assess librari pool load onto flowcel
ensur novaseq gener high-qual run without risk lose flowcel talk
present novaseq show one color chemistri iseq number microbi applic
iseq use current
ashg confer american societi human genet ashg remain import
confer genom research lab director biopharma scientist clinician genet
counselor come gain understand latest trend technolog impact
respect focu area confer still emphas lab product technolog
pure clinic product remain bridg clinic lab come
genom genet test
rate share outperform price target view
custom compet race reduc sequenc cost
manifest novaseq order believ sequenc market number
sampl depth coverag expand dramat next year novaseq
drive signific reduct sequenc cost hiseq
novaseq flow cell novaseq set path reach research
grade genom longer term price beyond high throughput platform
also continu drive double-digit growth desktop system includ nextseq
essenti key high growth market includ non-invas pre-nat test nipt
oncolog continu domin sequenc market world-wide address
market size accord life scienc genet test reproduct health
oncolog market share revenu market share sequenc unit
believ ilmn market share accuraci throughput enterpris level servic
product factor continu keep custom bound despit
custom consid higher price still direct strong competit sight
somewhat unbound market believ continu domin next-gen sequenc
keep drive sequenc cost lower lead elast demand sampl
share current trade price-to-earnings consensu ep averag
life scienc tool lst group multipl note potenti unbound
market opportun major popul develop develop world
touch sequenc form test next year use dcf
analysi beta long-term growth rate wacc arriv
price target believ remain strong forc sequenc market
see revenu growth continu outer year addit believ long-term
growth rate conserv estim given sequenc repres somewhat
unbound market opportun view still applic continu
explor beyond current one
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
servic
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report leerink partner estim
